Overview
The goal of this retrospective study is to compare the long-term follow-up outcomes of pulses field ablation (PFA) Vs. radiofrequency ablation (RFA) for the patients with paroxysmal supraventricular tachycardia (PSVT). The main question to answer is:
Does the PFA was more effecient and safer that RFA for treatment of PSVT during procedure and after 1-year follow-up? Researchers will compare the acute and long-term efficiency and safety between PFA and RFA.
- Recieved PFA or RFA 1 year ago
- Finish the visit to the clinic at 1, 3, 6, 12 months for examinations and blood testings
- Patients recieved PFA and PFA under propensity matched comparison according to differen variety of PSVT
Description
The goal of this retrospective study is to compare the long-term follow-up outcomes of PFA Vs. RFA for the patients with PSVT. The main question to answer is:
Does the PFA was more effecient and safer that RFA for treatment of PSVT during procedure and after 1-year follow-up? Researchers will compare the acute and long-term efficiency and safety between PFA and RFA.
Eligibility
Inclusion Criteria:
- Patients with symptomatic PSVT including: atrioventricular nodal re-entrant tachycardia (AVNRT), atrioventricular re-entrant tachycardia (AVRT);
- Age range: 18 years old ≤ age ≤ 80 years old, with no gender restriction;
- Willing to receive the examinations and testings during one year follow-up required by the protocol;
- Voluntary signed informed consent.
Exclusion Criteria:
- Organic heart disease;
- History of cardiac surgery;
- Previous failed ablation of PSVT;
- Presence of any implants, such as a permanent pacemaker;
- Patients with invasive systemic infections or advanced malignant tumors;
- Contraindications for septal puncture or retrograde transaortic access surgery;
- Any condition that makes the use of heparin or aspirin inappropriate;
- Pregnant or lactating women;
- Inability to fully comply with the study procedures and follow-ups or to provide their own informed consent;
- Coexistence with other arrhythmias, such as atrial fibrillation.